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Abstract: High-surface-area porous coatings represent an interesting option to fabricate eluting stents
with additional functionalities, as controlled drug delivery and antibacterial resistance properties.
ZnO is a biocompatible material available in various high-surface-area morphologies, with promising
antibacterial properties. Hydrophilic 2-hydroxyethyl methacrylate (HEMA) polymers (pHEMA)
have been widely investigated for their biomedical applications, thanks to their biocompatibility,
absence of toxicity, and tunable swelling properties. This work aims to demonstrate the use of porous
ZnO/polymer bilayer coatings for future drug eluting stent applications. Sputtered mesoporous
ZnO layers were coated with pHEMA and p(HEMA-co-acrylic acid (AA)) films through vacuum
infiltration and drop-casting methods. The last approach was found to be the most suitable one for
achieving a good polymer infiltration within the ZnO matrix and to avoid the mechanical detachment
of the porous film from the substrate. The corresponding release properties were evaluated by
loading a fluorescent dye in the host ZnO matrix, before drop-casting the polymer coating. For pure
ZnO, the release of the dye was completed after 2 h. For ZnO/pHEMA, the sustained release of
the molecule was achieved with only 30% released after 2 h and 100% released after seven days.
In this case, the pH-triggered delivery properties were also demonstrated by switching from neutral
to acidic pH conditions. No significant changes were obtained for the ZnO/p(HEMA-co-AA) system,
which exhibited a faster swelling behavior and a release profile similar to pure ZnO.
Keywords: zinc oxide; porous thin films; 2-hydroxyethyl methacrylate; drug delivery; pH-triggered
release; eluting coatings
1. Introduction
High-surface-area porous coatings for implantable biomedical devices represent an intriguing
solution to confer the device additional functionalities with respect to the uncoated implant [1].
In this regard, drug-releasing devices featuring biocompatibility, biostability, antibacterial resistance
properties, efficient drug loading and delivery should be pursued. For such purposes, the most
commonly used materials are polymers [2]; new generation carbon-based materials, such as graphene
and graphene oxide [3]; and other inorganic porous materials like anodized alumina [4], titania
nanotubes [5], and porous silicon coatings [6]. However, most of these are limited by their
unpredictable rather than poor degradation behaviors, also resulting in toxic reaction products in some
cases, thereby inducing undesirable inflammatory reactions in the body.
Nowadays, one of the main limitation affecting ureteral stents’ operation is the formation of
progressive encrustations due to inorganic salt deposition and bacteria biofilm formation, resulting
in the total occlusion of the stent lumen in the worst case, especially for prolonged indwelling times.
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Therefore, new practical solutions are strongly required to face the above-mentioned critical issues,
that is, to fight the infections rising in patients because of bacteria biofilm formation and to guarantee
a suitable urine drainage, finally avoiding the stent exchange at regular intervals. Within this scope,
some solutions have been developed so far, and which have mostly involved the surface modification
of the stent by the deposition of functional coatings such as antimicrobial silver [7], hydrophilic coating
with hydrogel (like Hydromer®) [8], heparin [9], plasma-deposited diamond-like amorphous carbon
coatings [10], and many more. With these solutions, both the bacterial adhesion and the formation
of inorganic encrustation have been limited to some extent. To further improve and intelligently
render the ureteral stent performances, however, drug eluting capabilities [11–13] and the complete
biodegradation [14] of the stent materials would be required. Presently, only some efforts in this
direction are in place, with some satisfactory results in animal models using polylactic acid (PLA)
polymers [15]. However, the incomplete dissolution of the stent, leading to the permanence in the
ureter to small polymer fragments [16], causing an obstruction to the urine flow that is then impossible
to be further removed without surgical intervention. Concerning drug eluting stents, some antibiotics,
like triclosan, have not received approval from the Food and Drug Administration (FDA) because of
their potential for developing antibiotic resistance [17]. Thus, in this prospect, the use of intrinsically
antimicrobial materials (i.e., nanoantibiotics) [18,19] with a nanostructured surface able also to host
therapeutic molecules will be of great interest.
Zinc oxide (ZnO) is attracting increasing interest for a wide plethora of application fields,
including the biomedical one [20,21], in particular as an antibacterial agent [22]. ZnO is a wide
band-gap metal oxide n-type semiconductor, showing a generous surface chemistry, interesting
optical and piezoelectric properties, and promising photocatalytic activities at the same time.
It has been successfully explored for new-generation energy harvesting systems [23], sensors [24],
and photocatalytic systems [25]. Moreover, ZnO in the bulk form has already been considered as safe
and has been approved by the FDA [26]. More interestingly, various ZnO morphologies and shapes
showing high-surface areas and porous structures coupled with a generous surface chemistry may be
easily prepared and functionalized [27]. Some examples include porous thin films [28], nanowires [29],
nanocrystals [30], and flower-like structures [31], which are easily obtainable by following numerous
dry and wet synthetic approaches, like sol–gel strategies, hydrothermal routes, and vapor-phase
deposition methods.
At first, the investigation of ZnO nanomaterials for biomedical applications was highly focused
on their use in the fabrication of biosensing units [32] able to detect various bio moieties, like proteins,
glucose, and acid uric. More recently, ZnO nanomaterials have been successfully explored for tissue
engineering [33], drug-delivery [34], and anticancer therapeutics [35] as well. The active promotion of
cell growth and proliferation, together with its proangiogenic, osteogenic, and antibacterial properties,
have been reported [36], and the efficacy of ZnO in promoting wound healing and the formation of
new bone tissue has been successfully demonstrated. High-surface area ZnO morphologies have been
investigated for drug delivery applications as well [34]. For this purpose, the high sensitivity of ZnO
against pH variations was successfully exploited and for different ZnO nanostructures, which exhibited
pH-triggered release properties for various drug molecules. Moreover, ZnO can be successfully
used in photodynamic therapy, thanks to its reactive oxygen species (ROS) generation properties
under UV irradiation in aqueous media [35]. Finally, the combination of a broad visible emission
spectrum, strong luminescence, and the ability to generate ROS and work as a drug delivery system,
also make ZnO nanostructures promising candidates for theranostic platforms with both imaging and
therapeutically-active properties.
Hydrophilic 2-hydroxyethyl methacrylate polymers (pHEMA) are widely used in biomedical
applications because of their biodegradability and biocompatibility [37]. Moreover, tunable swelling
behaviors can be easily obtained with the addition of specific monomers like acrylic acid [38,39].
Several works demonstrated the successful use of pHEMA as drug delivery systems [40] in
ophthalmology [41] and in plastic surgery.
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In this work, the combination of the above-mentioned properties of porous ZnO, that is,
its drug delivery, biodegradation, and prospective anti-microbial effects, were combined with a
soft biodegradable polymeric matrix intended as a smart coating for ureteral stents. In particular,
mesoporous ZnO coatings were obtained by a facile two-step synthetic approach, combining the
sputtering technique and thermal oxidation. The corresponding molecule loading and release
properties were evaluated by considering calcein (i.e., a fluorescent dye) as a model drug molecule.
The as-prepared ZnO films exhibited interesting molecule loading capacities because of their
high surface area and generous surface chemistry, but they also displayed fast and uncontrolled
release kinetics. To overcome this limitation, biocompatible 2-hydroxyethyl methacrylate (pHEMA)
and p(HEMA-co-acrylic acid (AA)) polymer coatings were deposited by vacuum infiltration and
drop-casting techniques, atop of the calcein-loaded mesoporous ZnO matrix. The release behavior
of the resulting ZnO/pHEMA and ZnO/p(HEMA-co-AA) bilayer structures was evaluated in vitro,
and the effect of switching the pH conditions from neutral to slightly acidic on the release properties
was evaluated.
2. Materials and Methods
2.1. Preparation of Porous ZnO Thin Films
Porous ZnO thin films were prepared by following a two-step synthetic approach [34], involving
the deposition of metallic Zn films by sputtering, and a thermal oxidation process. In the first step,
porous Zn layers were deposited at room temperature on silicon (Si; 100-oriented; p-type) substrates
(~1 cm2 area) by radio-frequency (RF, 13.56 MHz) magnetron sputtering (from Elettrorava, Venaria,
Italy; see Figure S1 of Supporting Information (SI) for further details on sputtering machine geometry).
Si was selected as a reference substrate material because of its smooth and flat surface, and the absence
of any porosity, thus avoiding any artifact during the loading and release experiments. Moreover,
it facilitates the preparation of samples for cross-section imaging, because it can be easily cut along a
specific crystallographic direction. Zn depositions were carried out starting from a four-inch diameter
metallic Zn target, in a pure Ar atmosphere, with a fixed deposition pressure of 5 × 10−3 Torr, and a
RF power density of 0.66 W·cm−2. The overall deposition time was set to 4 h and the final average
thickness of the Zn layer was 10 µm. After the deposition, the Zn/Si samples were thermally oxidized
in a muffle furnace (L-401K2RN from Nabertherm™, Lilienthal, Germany) at 380 ◦C (ramp rate
150 ◦C/h), in air for 2 h. Before starting the Zn deposition, the Si substrates were properly cleaned in
an ultrasonic bath of acetone and ethanol (10 min for each washing cycle), and were dried under a
nitrogen flow (99.999% purity).
2.2. Preparation of PolyHEMA (pHEMA) and Poly(HEMA-co-AA)
2-hydroxyethyl methacrylate (HEMA, 99%), acrylic acid (AA), and 2,2′-azobis(2-methylpropionitrile)
(AIBN, 98%) were obtained from Sigma-Aldrich (Darmstadt, Germany). Ethanol and methanol were
from POCh (Gliwice, Poland). The monomers (HEMA and AA) were purified from inhibitors using
vacuum distillation, and were stored in a refrigerator until use. The other reagents were used as
received, without further purification. The synthesis of the homopolymer (pHEMA) and copolymer
p(HEMA-co-AA) was performed with the use of radical polymerization in the toluene solution.
The appropriate amounts of monomer HEMA or mixture of HEMA and AA (2.75:1 molar mixture) were
mixed with the initiator, AIBN (2 wt %). The polymerization reaction was carried out under a nitrogen
atmosphere at 70 ◦C for 8 h. After the completion of the polymerization, the obtained polymers were
filtered and dried under a vacuum. The weight-average molar mass (Mw) and molar-mass dispersity
(PDI), determined by the gel permeation chromatography (GPC) method were as follows: 12,500 Da
and 1.41 for pHEMA, respectively, and 8500 Da and 1.35 for p(HEMA-co-AA) respectively.
Coatings 2018, 8, 376 4 of 15
2.3. Preparation of ZnO/Polymer Bilayer Coatings
The pHEMA and p(HEMA-co-AA) polymer solutions (10 wt %) were prepared by mixing each
polymer (396 mg) in methanol (5 mL), under magnetic stirring at room temperature. The pHEMA
and p(HEMA-co-AA) films were obtained starting from the as-prepared solutions, by following two
separate deposition approaches: (i) vacuum infiltration and (ii) drop-casting technique. In the first case,
the ZnO/Si samples were placed at the bottom of a glass round-bottom flask connected to a rotary
pump for creating low vacuum conditions. Then, 100 µL of the polymer solution was injected inside
the reactor using a syringe through a rubber septum, and was left in static vacuum pumping conditions
for 30 min. Then, the vacuum was set for an additional 30 min to promote solvent evaporation and
the stabilization of the polymer film. A schematic representation of the apparatus used for vacuum
infiltration is shown in Figure S2 of SI. In the second approach, the polymer solution (100 µL) was
drop-casted directly atop the porous ZnO surface. Then, the solvent evaporation was obtained by
drying the samples overnight at room temperature.
2.4. Calcein Loading and Release Experiments
The loading experiments were performed in simulated body fluid (SBF; pH 7.4), prepared
according to Kokubo’s protocol [42]. Then, 9.34 mg of fluorescent calcein dye (Carl Roth, 622.55 molar
mass) was dissolved in 15 mL SBF, at room temperature, under continuous stirring (200 rpm) for 30 min.
The calcein was loaded by soaking the porous ZnO/Si samples for 2 h in 2 mL of the loading solution
(1 × 10−3 M), in orbital shaking conditions (200 rpm) at room temperature. After the calcein loading,
all of the samples were stored in the dark and were air-dried overnight. Then, each sample was diced
in two equal parts (each one with dimension of ~0.5 cm2). The release experiments were carried out in
duplicate, by soaking the samples in 5 mL of the release solution, that is, SBF or 5.8-buffered solution,
in orbital conditions (200 rpm) at 37 ◦C. Then, 100 µL of aliquot was collected from each release
solution at specific points of time (5 min, 15 min, 30 min, 60 min, 120 min, 24 h, 48 h, 72 h, and 7 days),
and analyzed using UV-Vis spectroscopy. The molecule release profile was then constructed by
considering the characteristic calcein UV absorbance peak at 473 nm. This was compared with a
calibration curve obtained by evaluating the UV absorbance value at 473 nm for a series of calcein
dilutions (from 1 × 10−6 M to 1 × 10−3 M), prepared both in the SBF and pH 5.8 buffered solutions.
The amount of calcein at each release time and the corresponding cumulative release profiles were
obtained according to the literature [34]. All of the loading and release experiments were performed in
dark conditions so as to prevent any degradation of the fluorescent dye.
2.5. Characterization Setup
The attenuated total reflectance (ATR)-FTIR spectra of the polymers were recorded using the
Tensor 27 spectrometer (Bruker, Bremen, Germany), equipped with a diamond crystal. The spectrum
was made in the spectral range of 4000–600 cm−1, with a resolution of 4 cm−1, and with 16 scans per
spectrum. The weight-average molar mass (Mw) and the molar-mass dispersity (PDI) of the polymer
and copolymer samples were determined using the gel permeation chromatography (GPC) method,
with the use of Shimadzu LC-20AD liquid chromatograph equipped with an ELSD (Evaporative
Light Scattering Detector) detector (Shimadzu Kyoto Corporation, Kyoto, Japan), using two Phenogel
columns (pore sizes of 100 Å and 50 Å in series) and THF (tetrahydrofuran) as eluent with a flow rate of
1 mL min−1 at 35 ◦C. Monodistributed poly(methyl methacrylate) was used as the calibration standards.
Before the analyses, the studied polymers were dissolved in methanol/acetonitrile (50/50 v/v).
The 1H NMR spectra were obtained using a Bruker Avance 300 MSL spectrometer (Bruker, Bremen,
Germany) at the field strength of 300 MHz. The polymer solutions were prepared in deuterated
methanol. The morphology of the samples was evaluated by means of a field-emission scanning
electron microscope (FESEM, Merlin Carl Zeiss AG, Oberkochen, Germany). The ATR-FTIR spectra of
the ZnO/polymer samples were acquired with a 4 cm−1 resolution and 16 scans per spectrum were
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accumulated, using a Nicolet 5700 FTIR Spectrometer (ThermoFisher, Waltham, MA, USA), and were
background subtracted. The UV-VIS absorbance spectra were collected in the range of 200–800 nm,
by means of a microplate reader (Multiskan™ FC Microplate Photometer, from ThermoFisher Scientific,
Waltham, MA, USA). All of the UV spectra were background subtracted.
3. Results and Discussion
3.1. Characterization of PolyHEMA (pHEMA) and Poly(HEMA-co-AA)
The FTIR spectra of the homopolymer pHEMA and copolymer p(HEMA-co-AA) are presented
in Figure 1. It is apparent that both the spectra contain similar peaks because of the similar structure
of the monomers used for the synthesis of the polymers. For the pure pHEMA, the absorption band
derived from the hydroxyl group vibration is observed at 3400 cm−1. The sharp absorption band at
1721 cm−1 corresponds to the carbonyl group (C=O) vibration. In the spectrum of the copolymer,
the absorption band centered at 1720 cm−1 is also derived from the vibrations of the C=O group from
HEMA, as well as from the associated carboxylic acid group. The position of the carbonyl group
peak vibration suggests that most of the carboxylic acid groups are associated with the intermolecular
hydrogen bonds formed between the HEMA derived moieties and the acid groups [43,44]. Moreover,
the broad absorption band in the spectrum region 3200–3600 cm−1 corresponding to the OH group
vibrations also confirms that the hydrogen bonds are formed in the structure of p(HEMA-co-AA).
Figure 1. The FTIR spectra of the polymers hydrophilic 2-hydroxyethyl methacrylate p(HEMA) (black)
and p(HEMA-co-acrylic acid (AA)) (red).
The 1H NMR spectra of pHEMA and its copolymer with acrylic acid are presented in Figure 2,
and confirm the chemical structure of the prepared materials. The assignment of the peaks is
given in Figure 2. For pHEMA, the characteristic signals are as follows: δ = 1.1 ppm, 0.93 ppm
(–CH3, a); δ = 1.94–2.02 ppm (–CH2–, b); δ = 3.77 ppm (–CH2–OH, d); δ = 4.04 ppm (–CH2–O, c).
For p(HEMA-co-AA), the new signal at δ = 2.65 ppm characteristic for –CH–COOH (e) is visible.
The ratio of HEMA to AA in the copolymer, calculated on the basis of the peak intensities denoted as d
and e in the spectrum of the copolymer, was 5.9:1. However, the molar feed ratio of the monomers was
2.75:1, respectively. This means that in the final structure of the copolymer, two times less of the AA
monomer was incorporated than was assumed.
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Figure 2. The 1H NMR spectra of pHEMA and p(HEMA-co-AA).
3.2. Characterization of Porous ZnO/Polymer Bilayer Systems
The presence of pHEMA and p(HEMA-co-AA) polymer coatings atop of the mesoporous ZnO
films was first confirmed by the FTIR analyses (Figure S3 of SI).
Figure 3 shows the evolution of the surface morphology for the mesoporous ZnO matrix, before
and after drop-casting the two different polymer solutions (i.e., pHEMA and p(HEMA-co-AA)).
If the starting ZnO sample is considered (Figure 3a), a rough surface with nano-branched ZnO
crystals forming cavities and a mesoporous structure can be observed. The corresponding degree
of porosity, that is, 14 m2 g−1, with a pore volume of 0.095 cm3 g−1, was previously estimated
by nitrogen adsorption–desorption isotherm analyses [45]. After drop casting the pHEMA and
p(HEMA-co-AA) solutions, the morphology heavily changes, with a flat and smooth surface in both
the cases (Figure 3b,c), indicating a complete and uniform coating of the polymers on the ZnO porous
structure. If the vacuum-infiltrated ZnO/polymer samples are considered (Figure S4 of SI), surfaces
featuring similar morphologies can be observed as well. Therefore, no substantial differences affecting
the surface morphology of the ZnO/polymer samples are detected if the drop-casting and vacuum
infiltration methods are considered.
Figure 3. Top-view field-emission scanning electron microscope (FESEM) images of porous ZnO thin
films: (a) before polymer infiltration; (b) after drop-casting the pHEMA solution; (c) after drop-casting
the p(HEMA-co-AA) solution.
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In contrast, the cross-section of the vacuum-infiltrated and drop-casted samples is strongly
different if it is analyzed. Figure 4 shows the cross-section view of the ZnO/pHEMA bilayer samples
obtained after the vacuum infiltration. A high-magnification view of the structure is reported in
Figure 4a, with red arrows highlighting that the infiltration of pHEMA within the mesoporous and
nanostructured ZnO matrix has successfully occurred, without the clogging of the existing pores
at all. The formation of a well-defined and continuous interface between the pHEMA coating and
the underlying mesoporous ZnO structure is also visible in Figure 4b. However, if the ZnO/Si
substrate interface is considered (Figure 4c,d), the presence of cracks within the ZnO layer is noticed,
and suggests a possible detachment of ZnO from the Si support.
Figure 4. Cross-section view FESEM images for porous ZnO thin film on a Si substrate after vacuum
infiltration with a pHEMA solution (10 wt %). (a) Infiltration of pHEMA (red arrows) within the porous
ZnO matrix; (b) view of the interface between the pHEMA coating and the underlying ZnO matrix;
(c,d) view of the cracks within the ZnO layer.
Figure 5a,b shows that the vacuum infiltration method was also suitable for infiltrating the
copolymer within the mesoporous ZnO matrix, featuring morphological characteristics similar to those
that were obtained for the homopolymer case (see Figure 5a,b to compare). The interface between
the copolymer coating and the mesoporous ZnO structure is well-defined again, despite the ZnO/Si
substrate interface exhibiting also the presence of cracks (Figure 5c,d).
Figure 5. Cont.
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Figure 5. Cross-section view FESEM images for porous ZnO thin film on a Si substrate after vacuum
infiltration with a p(HEMA-co-AA) solution (10 wt %). (a) Infiltration of p(HEMA-co-AA) (red arrows)
within the porous ZnO matrix; (b) view of the interface between the p(HEMA-co-AA) coating and the
underlying ZnO matrix; (c,d) view of the cracks within the ZnO layer.
The morphology of the ZnO/polymer samples obtained using the drop-casting technique is
shown in Figure 6. Both the polymers, that is, pHEMA and p(HEMA-co-AA), well infiltrated the ZnO
matrix, as highlighted by the red arrows of Figure 6a,c. The uniform impregnation of the matrix shows
similar characteristics, and a well-defined interface between ZnO and the polymer coating is obtained
also in this case, as is visible from Figure 6b,d.
Figure 6. Cross-section view FESEM images for porous ZnO thin film on an Si substrate after
drop-casting the polymer solution: (a,b) pHEMA; (c,d) p(HEMA-co-AA). The presence of fragments
alongside the cross-section is due to the cleavage of the samples, which induced the breaking of the
polymer coating in some cases.
The cracks within the mesoporous ZnO matrix and the resulting partial detachment from the Si
support observed for the vacuum-infiltrated samples can be inferred to the presence of low-vacuum
conditions during the infiltration process, which most likely induced a faster solvent evaporation
than for the drop-casting approach, and led to a rapid expansion of the ZnO structure, also due to the
possible presence of air entrapped within the ZnO pores. This conclusion is strengthened by the FESEM
analyses performed on the drop-casted ZnO/polymer samples (Figure 6), highlighting that no crack
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within the ZnO film near the substrate is present. Actually, drop-casting was performed at atmospheric
pressure, without forcing the methanol evaporation using low vacuum conditions. Another limitation
of the vacuum infiltration approach is related to the polymer film thickness. Independently of the
considered polymer, the vacuum-infiltrated coatings had an average thickness of around 30 µm.
On the other hand, the drop-casting of the polymeric solutions allowed for avoiding the detachment
of the porous ZnO matrix from the Si support, and to limit the polymer coating thickness at the same
time, which was around 3 µm. Therefore, by considering the absence of any detachment and cracks,
high structural stability and integrity, and the reduced polymer coating thickness, the drop-casting
method was selected as the best approach in order to fabricate the ZnO/polymer bilayer systems,
and the corresponding calcein release properties were thereafter evaluated.
3.3. pH-Triggered Release of Calcein from Drop-Casted ZnO/pHEMA and ZnO/p(HEMA-co-AA)
Bilayer Coatings
Calcein was loaded in the porous ZnO films for 2 h at room temperature. A picture representative
of the calcein-loaded ZnO sample is reported in Figure 7a, which highlights the color change of the
ZnO sample after calcein adsorption, and witnesses the successful loading of the fluorescent dye
within the host porous matrix.
Figure 7. Pictures representative of the following: (a) porous ZnO thin film on Si wafer, after calcein
loading; (b) sample ZnO/pHEMA after calcein release in simulated body fluid (SBF) for 24 h; (c) sample
ZnO/p(HEMA-co-AA) after calcein release in SBF for 24 h.
The calcein release was first monitored for the pure ZnO samples in the SBF solution (pH 7.4) at
37 ◦C, by considering the time evolution of the UV absorption peak characteristic for the calcein dye
(Figure S5 of SI). The corresponding release profile (Figure 8a, black line) follows a pseudo-first-order
exponential decay law (Figure 8b, dotted black line), with a release rate constant of 0.33 min−1,
representing that the calcein release from the porous ZnO film is governed by a simple diffusion
mechanism. An important burst effect characterizing the release profile is present, with more than
90% of the calcein released within 30 min, and the complete release (100%) occurring after 120 min.
The molecule release profile was then monitored in similar conditions (SBF, pH 7.4, 37 ◦C) after drop
casting pHEMA and p(HEMA-co-AA) polymer films atop of the calcein-loaded porous ZnO matrix.
The UV spectra of the corresponding release solutions are reported in Figure S6 of SI. Independently
of the kind of polymer, the release kinetic appeared slower, as visible from the release profiles of
Figure 8a. However, Figure 8b highlights some of the important differences between the two family of
samples, especially for the short release times. For the sample ZnO/pHEMA, the release was more
effectively slowed down, with only 32% calcein delivered after 120 min, then approaching 60% after
24 h. This incomplete calcein release is further represented in Figure 7b, showing that the sample
of ZnO/pHEMA still appeared colored after 24 h. Hence, a sustained delivery was demonstrated
in this case, with the calcein release continuing for an overall time period of seven days. For the
sample ZnO/p(HEMA-co-AA), a faster calcein release was observed, with ~90% calcein delivered
after 120 min and 100% delivered after 24 h. This is represented in Figure 7c as well, showing that after
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24 h, the sample was totally white (i.e., the typical color of pure ZnO film). Anyway, despite showing a
faster kinetic than for ZnO/pHEMA, the presence of the copolymer coating partially mitigated the
burst effect affecting the pure ZnO.
To evaluate the effect of the pH variation on calcein delivery, the release experiments were also
performed in a buffered pH 5.8 solution at 37 ◦C. It is actually aimed at exerting control over the
delivery kinetics in an environment that can be physiologically achieved in ureters. The acidification
of urine is both a physiological and therapeutic process, which can be obtained by diet, acidifying
drugs or compounds, metabolism, or diseases [46,47]. As urinary acidification at a pH below 5.5 poses
a substantial risk of uric acid precipitation (although this pH would be protective against calcium
phosphate precipitation) [48], in this study, we decided to maintain our acidification degree at a
physiological value of pH 5.8.
Figure 8. Cumulative release profile for calcein: (a) within 7 days; (b) within 120 min; (c) within
120 min, by changing the pH of the release solution.
Table 1. Kinetic parameters of calcein released from pure ZnO and ZnO/polymer systems.
p(HEMA)—polymers hydrophilic 2-hydroxyethyl methacrylate; AA—acrylic acid.
Material pH (w120min/w0), % K (min−1) X2
ZnO 7.4 100 0.33 ± 0.05 0.98
ZnO/pHEMA 7.4 32 0.03 ± 0.01 0.98
5.8 92 0.05 ± 0.01 0.95
ZnO/p(HEMA-co-AA) 7.4 93 0.38 ± 0.08 0.98
5.8 100 0.21 ± 0.07 0.85
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For pure ZnO, the sudden dissolution of the porous matrix occurred after soaking the sample
for few minutes, because of the fast degradation typical of ZnO-based materials when interacting
with acidic media [30,49]. Therefore, a quantitative evaluation of the calcein release for the pure ZnO
was only possible for neutral pH conditions. On the other hand, such degradation was prevented
if the ZnO/polymer bilayer systems are considered. This is due to the presence of the polymer
coatings, which successfully worked as barrier layers and prevented the sudden dissolution of the
mesoporous ZnO matrix upon interaction with an acidic environment. As previously observed,
the pure ZnO matrix showed a fast calcein delivery. After drop-casting the polymers, the kinetic
release was generally slowed down, especially when the homopolymer pHEMA was considered.
A similar behavior was found in acidic conditions as well, as shown in Figure 8b. However, for the
sample of ZnO/p(HEMA-co-AA), the release kinetic did not seem to be significantly improved, as 100%
calcein was released after 120 min (i.e., the same release time as obtained for pure ZnO). However,
a lower kinetic can be observed for shorter release times; after 60 min, 86% calcein was released
against the 98% measured for pure ZnO. If the sample ZnO/pHEMA is considered, a slightly different
behavior is observed, with 80% calcein released after 60 min, approaching 100% only after 24 h.
The interesting pH-responsive behavior of the sample of ZnO/pHEMA is more effectively visible
for shorter times (120 min), as reported in Figure 8c. It can be observed that, for neutral pH conditions,
the presence of pHEMA successfully allowed for controlling the calcein delivery with respect to pure
ZnO. The stability of the ZnO/pHEMA system, once interacting with SBF solution, also allowed
the sustained calcein release for up to seven days, while the complete delivery occurred after only
120 min for the raw ZnO matrix. Upon interaction with a slight acidic environment, the swelling
of the HEMA polymer was increased [38], thereby accelerating the kinetic release with respect to
the neutral pH conditions. This effect was more pronounced for the copolymer coating. Despite
acrylic acid being a pH-sensitive monomer, its ability to improve the swelling properties of HEMA is
also recognized [38,39]. This pronounced swelling effect, already observed in neutral pH conditions,
was further visible at the end of the release experiment (i.e., 100% calcein release); the presence of the
copolymer coating atop the porous ZnO matrix was no longer visible. On the contrary, the pHEMA
coating was still present at the same point of time. However, it is worth mentioning that some
micrometric defects started to be visible as well, as shown in Figure 9.
Figure 9. FESEM images of the sample of ZnO/pHEMA at the end of the release experiment in SBF,
at different magnifications, namely: (a) 100×; (b) 1000×.
The successfulness of the ZnO/pHEMA bilayer system for the sustained calcein delivery is
well-represented considering the corresponding kinetic parameters listed in Table 1. It can be observed
that, independently of the pH value, the presence of pHEMA effectively allowed for the reduction of
the kinetic release, with respect to pure ZnO. More interestingly, it is also observable that the calcein
release is pH-triggered, in this case; neutral conditions highly lower the release of calcein, while it can
be increased in the presence of a slight acidic environment. Even though all of the profiles follow the
same pseudo-first-order exponential decay law, representing the diffusion mechanisms, the release
rate constant drops to 0.03 min−1 and 0.05 min−1 for the ZnO/pHEMA bilayer system at pH 7.4
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and 5.8, respectively. For the copolymer coating, the kinetic constant is slightly equal to pure ZnO
(0.38 min−1). It is worth mentioning that, for the acidic media, the complete calcein release was reached
after 24 h in the best case, and after shorter release times in the others. This was due to the complete
degradation of the polymer coatings, which also induced the dissolution of the mesoporous ZnO
film. This result also confirms the potential biodegradability of the developed coatings for further
ureteral stent applications. For neutral pH conditions, the polymer coating was only partially damaged
(Figure 9), with the micrometric holes working as preferential channels along which calcein could
easily diffuse out from the porous ZnO matrix.
Finally, it can be summarized that two interesting effects are observed for the sample
ZnO/pHEMA, as follows: (1) with respect to pure ZnO, the presence of the polymer pHEMA
lowered the kinetic at pH conditions similar to those of the urinary system, and a sustained release
is obtained for seven days; (2) for slightly acidic conditions (pH 5.8), it is possible to monitor the
ZnO degradation and to accelerate the release kinetics of the overall ZnO/pHEMA system at the
same time, also avoiding the undesirable burst effect observed for pure ZnO. The abovementioned
properties envision the future possibilities in the use of ZnO/pHEMA coatings for drug eluting
ureteral stents with sustained and pH-controlled delivery properties obtained by changing the pH
conditions of the stent environment. Usually, acidifying drugs that temporarily decrease the urine pH
are administered to the patients in order to dissolve the calcium phosphate encrustations affecting
the urinary tract and the stent in place [48,50]. Despite the different time scales existing between
the kinetic release of the proposed ZnO/polymer coatings (exhausting within 7 days in the best
scenario) and the development of encrustations (several weeks), this local pH increase could also be
effectively exploited to activate/accelerate the release of other drug molecules, like anti-inflammatory
or antibiotics, previously loaded within the ZnO/pHEMA eluting coating.
4. Conclusions
Porous ZnO thin films coupled with pHEMA and p(HEMA-co-AA) polymer coatings were
successfully fabricated by vacuum infiltration and drop-casting techniques. The morphological
analyses pointed out that drop-casting was the most suitable method to avoid the development
of cracks within the porous ZnO matrix, and for an appropriate polymer film thickness as well.
For the pure ZnO matrix, the release experiments showed an important burst effect and a fast kinetic,
with 100% calcein released after 120 min. On the other hand, the presence of the polymer coatings
partially limited the undesirable burst effect and slowed down the calcein kinetic release. In particular,
the pHEMA coating successfully allowed the following: (i) to create a barrier layer that prevented the
sudden release of the molecule loaded within the porous ZnO matrix; (ii) to achieve a sustained release
for up to seven days in neutral pH conditions; (iii) to implement a pH-triggered delivery system by
moving from neutral to acidic pH conditions.
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of the apparatus used for the preparation of ZnO/polymer bilayer samples by vacuum infiltration method,
Figure S3: FTIR spectra for ZnO/pHEMA and ZnO/p(HEMA-co-AA) samples, obtained by (a) drop-casting and
(b) vacuum infiltration method. No additional contributions coming from the porous ZnO layer are detected in
both the cases because the characteristic ZnO IR modes fall out from the detection range of the ATR-FTIR setup,
i.e., at wavenumber lower than 525 cm−1, Figure S4: Top-view FESEM images of porous ZnO thin films on Si
substrate: (a) before polymer infiltration; (b) after vacuum infiltration of the pHEMA solution; (c) after vacuum
infiltration of the p(HEMA-co-AA) solution. Scale bar is 200 nm, Figure S5: UV spectra of calcein release solutions
from the mesoporous ZnO matrix, performed in aqueous SBF solution at physiological pH conditions and 37 ◦C,
Figure S6: UV spectra of calcein release solutions for (a) ZnO/pHEMA at pH 7.4, (b) ZnO/pHEMA at pH 5.8,
(c) ZnO/p(HEMA-co-AA) at pH 7.4, (d) ZnO/p(HEMA-co-AA) at pH 5.8.
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